Explore 3 Stock Ideas & Industry Insights Download Free Report

Hepion Pharmaceuticals Inc

Company price
0.105 USD -0.04 ( 25.00%)
Last update at 2026-11-13T19:32:00Z
VOLUME
1582
Market Cap
7.13M

Momentum Score

…

Hepion Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatment for hepatocellular carcinoma (HCC), metabolic liver diseases, and chronic liver diseases in the United States. It developed Rencofilstat, a therapeutic drug candidate that binds and inhibits the function of a specific class of isomerase enzymes called cyclophilins that regulates protein folding, as well as preclinical experiments of Rencofilstat reflects decreased liver fibrosis; liver inflammation; liver tumor burden; and titers of HBV, HCV, and HDV. The company was formerly known as ContraVir Pharmaceuticals, Inc. and changed its name to Hepion Pharmaceuticals, Inc. in July 2019. Hepion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Morristown, New Jersey.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
0.10
Low
0.11
High
52 Week Price Range
0.03
Low
0.11
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Hepion Pharmaceuticals is a clinical-stage biopharma developing therapies for chronic liver diseases; its lead candidate CRV431 is a cyclophilin inhibitor being developed for NASH, liver fibrosis and related indications. Long-term drivers include clinical progress, potential approvals or partnerships, and the large unmet need for NASH and antifibrotic treatments; investors may view the differentiated mechanism and multi-indication potential as attractive.
Key risks are clinical or regulatory failure, limited cash runway requiring additional financing, and significant competition and scientific uncertainty in NASH and liver therapeutics.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
0.14
Dividend Yield
-
Revenue TTM
0.00M
Revenue Per Share
-
Gross Profit TTM
0.00M
Debt / Equity
0.02
ROE
-125.64%
Net Debt
-1.77M
ROCE
-135.75%
Diluted EPS TTM
-0.03

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -8.28M -16.16M -49.34M -45.08M -32.72M
Net income -8.28M -13.19M -48.93M -42.20M -32.72M
Selling general administrative 3.32M 7.50M 9.62M 10.35M 10.01M
Selling and marketing expenses - - 0.07M - -
Gross profit - -0.03M -0.07M -0.08M -0.09M
Reconciled depreciation 0.00M 0.03M 0.07M 0.08M 0.09M
Ebit -3.76M -14.91M -45.26M -43.62M -30.40M
Ebitda -3.73M -14.88M -45.19M -43.54M -30.32M
Depreciation and amortization 0.03M 0.03M 0.07M 0.08M 0.09M
Operating income -4.16M -19.35M -45.26M -45.49M -30.40M
Other operating expenses 4.16M 19.35M 45.26M 43.62M 30.40M
Interest expense 0.02M 1.25M 0.01M 0.01M 0.01M
Tax provision 0.00M -2.97M -2.88M -2.88M -0.00M
Net interest income -0.02M -1.25M -0.01M -0.01M -0.01M
Non recurring - - - 1.87M -
Income tax expense - -2.97M -0.41M -2.88M 0.01M
Total revenue 0.00M 0.00M 0.00M 0.00M 0.00M
Total operating expenses 4.16M 19.35M 45.19M 43.62M 30.40M
Cost of revenue - 0.03M 0.07M 0.08M 0.09M
Total other income expense net -4.11M 3.18M -4.08M -1.46M -2.31M
Net income from continuing ops -8.28M -13.19M -44.68M -42.20M -32.72M
Net income applicable to common shares - - - -45.34M -32.72M
Preferred stock and other adjustments - - - 3.14M -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 3.07M 1.61M 18.09M 60.24M 103.55M
Intangible assets - - - 3.19M 3.19M
Other current assets 1.24M 1.21M 2.70M 5.31M 6.10M
Total liab 0.40M 3.48M 10.81M 10.39M 10.56M
Total stockholder equity 2.67M -1.86M 7.28M 49.86M 93.00M
Deferred long term liab - - - 0.41M -
Other current liab 0.08M 0.02M 0.39M 5.17M 2.99M
Common stock 0.00M 0.00M 0.00M 0.01M 0.01M
Capital stock 1.70M 1.70M 1.70M 1.70M 1.71M
Retained earnings -246.10M -237.82M -224.63M -175.70M -133.50M
Other liab - - - 2.50M 2.30M
Good will - - - 0.00M 1.87M
Other assets - - - 0.43M 0.58M
Cash 1.83M 0.41M 14.79M 51.19M 91.35M
Total current liabilities 0.30M 3.14M 5.29M 7.89M 8.21M
Current deferred revenue - - 2.44M - 2.51M
Net debt -1.77M 2.49M -14.58M -51.14M -91.03M
Short term debt 0.05M 2.90M 0.12M 0.05M 0.27M
Short long term debt 0.05M 2.90M - - -
Short long term debt total 0.05M 2.90M 0.21M 0.05M 0.32M
Other stockholder equity 247.06M 234.25M 230.29M 223.94M 224.79M
Property plant equipment - - - 0.08M 0.46M
Total current assets 3.07M 1.61M 17.49M 56.50M 97.45M
Net tangible assets - - - 44.97M 86.23M
Accounts payable 0.17M 0.22M 2.35M 2.67M 2.45M
Accumulated other comprehensive income 0.01M 0.01M -0.08M -0.09M -
Common stock total equity - - - 0.01M -
Preferred stock total equity - - - 1.70M -
Retained earnings total equity - - - -175.70M -
Non currrent assets other - 0.00M 0.30M 0.43M 0.58M
Non current assets total 0.00M 0.61M 0.61M 3.75M 6.10M
Capital lease obligations - 0.00M 0.21M 0.05M 0.32M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments -0.13M -0.60M -0.03M -0.01M -0.13M
Change to liabilities - - - 2.25M -1.07M
Total cashflows from investing activities -0.13M -0.60M - -0.01M -0.13M
Net borrowings -3.37M 0.00M - - -0.18M
Total cash from financing activities 4.83M 4.35M 4.49M -5.14M 81.98M
Change to operating activities - - - 0.91M -4.50M
Net income -8.28M -13.19M -48.93M -42.20M -32.72M
Change in cash 1.42M -14.38M -36.40M -40.16M 50.62M
Begin period cash flow 0.41M 14.79M 51.19M 91.35M 40.73M
End period cash flow 1.83M 0.41M 14.79M 51.19M 91.35M
Total cash from operating activities -3.27M -18.22M -40.89M -34.96M -31.22M
Issuance of capital stock 0.00M 2.50M 0.00M 17.86M 82.15M
Depreciation 0.00M 0.03M 0.07M 0.08M 0.09M
Other cashflows from investing activities - -0.60M - 0.00M -
Dividends paid - - 0.00M 0.01M 0.01M
Sale purchase of stock - - 0.00M -21.00M 0.18M
Other cashflows from financing activities -0.80M 1.85M 0.00M -2.00M -0.17M
Change to netincome - - - 4.01M 6.98M
Capital expenditures 0.00M 0.01M 0.01M 0.02M 0.13M
Cash flows other operating - - - 0.91M -
Cash and cash equivalents changes - - - -40.11M -
Change in working capital 0.49M -2.68M 2.97M 3.15M -5.57M
Stock based compensation 0.02M 0.79M 1.34M 2.55M 4.67M
Other non cash items 4.49M -3.16M 4.07M 1.46M 2.31M
Free cash flow -3.27M -18.22M -40.90M -34.98M -31.35M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to EBITDA (x)
HEPA
Hepion Pharmaceuticals Inc
-0.04
25.00%
0.10 - - - 41.86 1.16
NVO
Novo Nordisk A/S
0.98
2.41%
41.63 41.58 31.15 2.13 32.99 4.70
VRTX
Vertex Pharmaceuticals Inc
-4.02
0.74%
538.60 30.22 24.27 10.36 6.50 24.66
REGN
Regeneron Pharmaceuticals Inc
4.28
0.45%
955.47 29.07 20.12 7.57 3.82 19.42
ARGNF
argenx SE
64.70
7.19%
965.00 45.77 31.25 13.84 7.12 36.06

Profile*

Hepion Pharmaceuticals Inc

Hepion Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatment for hepatocellular carcinoma (HCC), metabolic liver diseases, and chronic liver diseases in the United States. It developed Rencofilstat, a therapeutic drug candidate that binds and inhibits the function of a specific class of isomerase enzymes called cyclophilins that regulates protein folding, as well as preclinical experiments of Rencofilstat reflects decreased liver fibrosis; liver inflammation; liver tumor burden; and titers of HBV, HCV, and HDV. The company was formerly known as ContraVir Pharmaceuticals, Inc. and changed its name to Hepion Pharmaceuticals, Inc. in July 2019. Hepion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Morristown, New Jersey.

55 Madison Avenue, Morristown, NJ, United States, 07960

732 902 4000

2

Name Title Year Born
Dr. Robert T. Foster B.Sc., BSc (Pharm), Ph.D., Pharm.D. Pres, CEO & Director 1958
Mr. John T. Cavan Chief Financial Officer 1958
Dr. Todd M. Hobbs M.D. Chief Medical Officer 1969
Dr. Launa J. Aspeslet Ph.D. Chief Operating Officer NA
Dr. Daren Ure Ph.D. Chief Scientific Officer NA
Sharen Pyatetskaya Director of Investor Relations NA
Dr. Daniel J. Trepanier Ph.D. Sr. VP of Drug Devel. NA
Dr. Patrick R. Mayo Ph.D. Sr. VP of Clinical Pharmacology NA
Dr. John Z. Sullivan-Bolyai Part-Time Consultant 1948
Dr. Stephen A. Harrison M.D. Member of Scientific Advisory Board & Consultant Medical Director NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Support

Hi! How can we help you today?

Loading…